CN Patent

CN116925080B — 作为Akt蛋白激酶抑制剂的化合物及其制备方法和用途

Assigned to Hangzhou Jianlai Biotechnology Co ltd · Expires 2025-12-12 · 0y expired

What this patent protects

本发明提供了一种式(I)所示的化合物，可用于预防和/或治疗肿瘤疾病，以及制备抗肿瘤药物。该化合物对蛋白激酶Akt具有很好的抑制活性，且具有优良的药代和药效活性。

USPTO Abstract

本发明提供了一种式(I)所示的化合物，可用于预防和/或治疗肿瘤疾病，以及制备抗肿瘤药物。该化合物对蛋白激酶Akt具有很好的抑制活性，且具有优良的药代和药效活性。

Drugs covered by this patent

Patent Metadata

Patent number: CN116925080B
Jurisdiction: CN
Classification: —
Expires: 2025-12-12
Drug substance claim: No
Drug product claim: No
Assignee: Hangzhou Jianlai Biotechnology Co ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.